BACKGROUND Schizophrenia is a common and severe mental disorder characterized by severe thought disturbances,hallucinations,delusions,and emotional instability.For some patients,conventional treatment methods may not ...BACKGROUND Schizophrenia is a common and severe mental disorder characterized by severe thought disturbances,hallucinations,delusions,and emotional instability.For some patients,conventional treatment methods may not effectively alleviate symptoms,necessitating the use of alternative therapeutic approaches.Modified electroconvulsive therapy(MECT)is an effective treatment modality for schizophrenia,inducing anti-depressive and antipsychotic effects through the stimulation of brain electrical activity.AIM To explore the impact of psychological nursing intervention(PNI)before and after MECT on the efficacy and quality of life of patients with schizophrenia.METHODS Eighty patients with schizophrenia who received MECT treatment from 2021 to 2023 were randomly divided into two groups:The intervention group(n=40)and the control group(n=40).The intervention group received PNI before and after MECT,while the control group received routine nursing care.The efficacy of MECT was evaluated by the Positive and Negative Syndrome Scale(PANSS)and the Clinical Global Impression Scale(CGI)before and after the treatment.The quality of life was assessed by the Short Form 36 Health Survey(SF-36)after the treatment.RESUITS The intervention group had significantly lower scores of PANSS and CGI than the control group after the treatment(P<0.05).The intervention group also had significantly higher scores of SF-36 than the control group in all domains except physical functioning(P<0.05).CONCLUSION PNI before and after MECT can improve the efficacy and quality of life of patients with schizophrenia.It is suggested that nurses should provide individualized and comprehensive psychological care for patients undergoing MECT to enhance their recovery and well-being.展开更多
Background The impairment of social function is widespread in the patients with chronic schizophrenia, which seriously affects family, life and work conditions.Aims The main purpose of this study was to investigate th...Background The impairment of social function is widespread in the patients with chronic schizophrenia, which seriously affects family, life and work conditions.Aims The main purpose of this study was to investigate the efficacy of paliperidone in the treatment of social function in chronic schizophrenia.Methods A total of 81 patients who met the standard criteria for schizophrenia and long-term hospitalised inpatients were randomly divided into the treatment group and normal control group following a 1-year prospective follow-up study. The reatment group(41 cases) used paliperidone extended-release tablets for reducing dosage, as appropriate, based on the original treatment strategy; and the control group(40 cases) used the former drugs. All patients were assessed using the Positive and Negative Symptom Scales(PANSS), and the Treatment Emergent Symptom Scale(TESS) was used to assess adverse drug reactions. The Hospitalised Psychiatric Patients' Social Functions Rating Scale(SSPI) was used to assess social function of participants before and after 8 weeks, 6 months and 1 year of treatment.Results At baseline there were no significant differences between the two groups in age, duration of illness, educational background and dosage of antipsychotic drugs(converted into chlorpromazine equivalency). There was statistically significant difference in PANSS positive symptoms by interaction effect(Fgroup×time=18.24, df=3237, p<0.001) and time effect(Ftime=21.66, df=3, p<0.01) and the difference in PANSS positive symptoms by grouping effect(Fgroup=0.68, df=1, p=0.41) was not statistically significant. The difference of grouping effect of PANSS negative symptoms(Fgroup=9.93, df=1, p=0.002), time effect(Ftime=279.15, df=3, p<0.001) and interaction effect(Fgroup×time=279.15, df=3237, p<0.001) were statistically significant. There were statistically significant differences in the grouping effect(Fgroup=6.59, df=1, p=0.012), time effect(Ftime=152.97, df=3, p<0.001) and interaction effect(Fgroup×time=148.82, df=3237, p<0.001) of PANSS general pathological symptoms, the same as the total score of the PANSS, which showed large differences in grouping effect(Fgroup=7.04, df=1, p=0.001), time effect(Ftime=210.78, df=3, p<0.001) and interaction effect(Fgroup×time=205.20, df=3237, p<0.01). We found in the total SSPI score, grouping effect(Fgroup=31.70, df=1, p<0.001), time effect(Ftime=161.84, df=3, p<0.001) and interaction effect(Fgroup×time=132.74, df=3237, p<0.001) were demonstrated to be significantly different. Even though adverse reactionsoccurred 7 times in the treatment group and 44 times in the control group based on the Treatment Emergent Symptom Scale(TESS), incidence rate was significantly lower than that of the control group(χ2=18.854, p<0.001).Conclusion Paliperidone can safely and effectively improve negative symptoms and social function in patients with chronic schizophrenia.展开更多
Objective:The efficacy and occurrence of adverse reactions of prescriptions containing phlegm-resolving Chinese medicine combined with risperidone in the treatment of schizophrenia were retrospectively studied by mean...Objective:The efficacy and occurrence of adverse reactions of prescriptions containing phlegm-resolving Chinese medicine combined with risperidone in the treatment of schizophrenia were retrospectively studied by means of meta-analysis.Methods:A variety of different Chinese and English databases were searched from January 1,2000 to May 1,2020.Review Manager 5.3 software was used to evaluate the methodological quality of the included studies.The positive and negative symptom scale(PANSS)was used as the evaluation standard to analyze the total scores,positive scores,negative scores and general psychopathological scores,clinical efficacy and safety of prescriptions containing phlegmresolving Chinese medicine combined with risperidone of schizophrenia.The heterogeneity test and sensitivity analysis were also carried out by Review Manager 5.3,and the potential publication bias was analyzed by"funnel plot".Results:A total of 1515 patients were included in 15 studies.Compared with control group of risperidone alone,the total PANSS scale score,positive symptom score,negative symptom score and general psychopathological score of the treatment group of phlegm-resolving Chinese medicine combined with risperidone were all lower than those of the control group(P=0.01,MD=-6.35,95%CI[-11.29,-1.40]),(P=0.04,MD=-1.42,95%CI[-2.74,-0.09]),(P<0.01,MD=-2.16,95%CI[-3.41,-0.91]),and(P<0.01,MD=-3.80,95%CI[-6.37,-1.24]),the clinical efficacy of phlegm-resolving Chinese medicine combined with risperidone treatment group on schizophrenia was better than that of the control group[P<0.01,RR=1.09,95%CI(1.05-1.13)].The incidence of adverse reactions was reduced(P=0.02,RR=0.56,95%CI[0.34-0.93]).Conclusion:The combination of prescriptions containing phlegm-resolving Chinese medicine and risperidone can effectively improve the efficacy of patients with schizophrenia and reduce the occurrence of adverse drug reactions compared with risperidone alone.展开更多
目的系统性评价静脉注射硝普钠(SNP)治疗精神分裂症(SZ)的有效性。方法通过PubMed、Web of Science、EMbase、Cochrane Library等英文数据,以及中国生物医学文献数据库、维普、万方和中国知网等中文数据库,检索有关静脉注射硝普钠治疗...目的系统性评价静脉注射硝普钠(SNP)治疗精神分裂症(SZ)的有效性。方法通过PubMed、Web of Science、EMbase、Cochrane Library等英文数据,以及中国生物医学文献数据库、维普、万方和中国知网等中文数据库,检索有关静脉注射硝普钠治疗精神分裂症的随机对照试验,所有数据库检索时限均于2020年11月7日截止。筛选文献、提取数据后,采用Review Manager 5.3软件进行Meta分析。结果最终纳入4个随机对照试验,共134例患者,结果显示,SNP组与对照组PANSS一般精神病理量表评分[MD=0.05(95%CI:-2.63,2.73),P>0.05]、PANSS阳性量表评分[MD=-0.76(95%CI:-1.74,0.23),P>0.05]、PANSS阴性量表评分[MD=-1.77(95%CI:-5.28,1.74),P>0.05]比较均无差异。敏感性分析后,SNP组与对照组PANSS阴性量表评分比较无差异[MD=-0.19(95%CI:-1.62,1.25),P>0.05]。SNP组与对照组BPRS-18量表评分比较有差异[MD=-5.91(95%CI:-11.42,-0.41),P<0.05],但异质性较高(I2=54%)。结论SZ患者对SNP耐受性较好,但与安慰剂比较,笔者无法得出SNP能够改善SZ相关精神症状的结论。展开更多
文摘BACKGROUND Schizophrenia is a common and severe mental disorder characterized by severe thought disturbances,hallucinations,delusions,and emotional instability.For some patients,conventional treatment methods may not effectively alleviate symptoms,necessitating the use of alternative therapeutic approaches.Modified electroconvulsive therapy(MECT)is an effective treatment modality for schizophrenia,inducing anti-depressive and antipsychotic effects through the stimulation of brain electrical activity.AIM To explore the impact of psychological nursing intervention(PNI)before and after MECT on the efficacy and quality of life of patients with schizophrenia.METHODS Eighty patients with schizophrenia who received MECT treatment from 2021 to 2023 were randomly divided into two groups:The intervention group(n=40)and the control group(n=40).The intervention group received PNI before and after MECT,while the control group received routine nursing care.The efficacy of MECT was evaluated by the Positive and Negative Syndrome Scale(PANSS)and the Clinical Global Impression Scale(CGI)before and after the treatment.The quality of life was assessed by the Short Form 36 Health Survey(SF-36)after the treatment.RESUITS The intervention group had significantly lower scores of PANSS and CGI than the control group after the treatment(P<0.05).The intervention group also had significantly higher scores of SF-36 than the control group in all domains except physical functioning(P<0.05).CONCLUSION PNI before and after MECT can improve the efficacy and quality of life of patients with schizophrenia.It is suggested that nurses should provide individualized and comprehensive psychological care for patients undergoing MECT to enhance their recovery and well-being.
基金supported in part by the National Science Fund of China(81771450,81471358)Shanghai Health Bureau scientific research grant(201540029)Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant(20152530)
文摘Background The impairment of social function is widespread in the patients with chronic schizophrenia, which seriously affects family, life and work conditions.Aims The main purpose of this study was to investigate the efficacy of paliperidone in the treatment of social function in chronic schizophrenia.Methods A total of 81 patients who met the standard criteria for schizophrenia and long-term hospitalised inpatients were randomly divided into the treatment group and normal control group following a 1-year prospective follow-up study. The reatment group(41 cases) used paliperidone extended-release tablets for reducing dosage, as appropriate, based on the original treatment strategy; and the control group(40 cases) used the former drugs. All patients were assessed using the Positive and Negative Symptom Scales(PANSS), and the Treatment Emergent Symptom Scale(TESS) was used to assess adverse drug reactions. The Hospitalised Psychiatric Patients' Social Functions Rating Scale(SSPI) was used to assess social function of participants before and after 8 weeks, 6 months and 1 year of treatment.Results At baseline there were no significant differences between the two groups in age, duration of illness, educational background and dosage of antipsychotic drugs(converted into chlorpromazine equivalency). There was statistically significant difference in PANSS positive symptoms by interaction effect(Fgroup×time=18.24, df=3237, p<0.001) and time effect(Ftime=21.66, df=3, p<0.01) and the difference in PANSS positive symptoms by grouping effect(Fgroup=0.68, df=1, p=0.41) was not statistically significant. The difference of grouping effect of PANSS negative symptoms(Fgroup=9.93, df=1, p=0.002), time effect(Ftime=279.15, df=3, p<0.001) and interaction effect(Fgroup×time=279.15, df=3237, p<0.001) were statistically significant. There were statistically significant differences in the grouping effect(Fgroup=6.59, df=1, p=0.012), time effect(Ftime=152.97, df=3, p<0.001) and interaction effect(Fgroup×time=148.82, df=3237, p<0.001) of PANSS general pathological symptoms, the same as the total score of the PANSS, which showed large differences in grouping effect(Fgroup=7.04, df=1, p=0.001), time effect(Ftime=210.78, df=3, p<0.001) and interaction effect(Fgroup×time=205.20, df=3237, p<0.01). We found in the total SSPI score, grouping effect(Fgroup=31.70, df=1, p<0.001), time effect(Ftime=161.84, df=3, p<0.001) and interaction effect(Fgroup×time=132.74, df=3237, p<0.001) were demonstrated to be significantly different. Even though adverse reactionsoccurred 7 times in the treatment group and 44 times in the control group based on the Treatment Emergent Symptom Scale(TESS), incidence rate was significantly lower than that of the control group(χ2=18.854, p<0.001).Conclusion Paliperidone can safely and effectively improve negative symptoms and social function in patients with chronic schizophrenia.
基金National Natural Scicnce Foundation of China(No.81973747,81873299)。
文摘Objective:The efficacy and occurrence of adverse reactions of prescriptions containing phlegm-resolving Chinese medicine combined with risperidone in the treatment of schizophrenia were retrospectively studied by means of meta-analysis.Methods:A variety of different Chinese and English databases were searched from January 1,2000 to May 1,2020.Review Manager 5.3 software was used to evaluate the methodological quality of the included studies.The positive and negative symptom scale(PANSS)was used as the evaluation standard to analyze the total scores,positive scores,negative scores and general psychopathological scores,clinical efficacy and safety of prescriptions containing phlegmresolving Chinese medicine combined with risperidone of schizophrenia.The heterogeneity test and sensitivity analysis were also carried out by Review Manager 5.3,and the potential publication bias was analyzed by"funnel plot".Results:A total of 1515 patients were included in 15 studies.Compared with control group of risperidone alone,the total PANSS scale score,positive symptom score,negative symptom score and general psychopathological score of the treatment group of phlegm-resolving Chinese medicine combined with risperidone were all lower than those of the control group(P=0.01,MD=-6.35,95%CI[-11.29,-1.40]),(P=0.04,MD=-1.42,95%CI[-2.74,-0.09]),(P<0.01,MD=-2.16,95%CI[-3.41,-0.91]),and(P<0.01,MD=-3.80,95%CI[-6.37,-1.24]),the clinical efficacy of phlegm-resolving Chinese medicine combined with risperidone treatment group on schizophrenia was better than that of the control group[P<0.01,RR=1.09,95%CI(1.05-1.13)].The incidence of adverse reactions was reduced(P=0.02,RR=0.56,95%CI[0.34-0.93]).Conclusion:The combination of prescriptions containing phlegm-resolving Chinese medicine and risperidone can effectively improve the efficacy of patients with schizophrenia and reduce the occurrence of adverse drug reactions compared with risperidone alone.
